AstraZeneca granted Fast Track Designation in the US for the development of Farxiga

AstraZeneca has been granted Fast Track Designation in the US for the development of Farxiga (dapagliflozin) to reduce the risk of hospitalisation for heart failure (hHF) or cardiovascular (CV) death in adults following an acute myocardial infarction (MI) or heart attack.

source https://www.pharmatutor.org/pharma-news/2020/astrazeneca-granted-fast-track-designation-in-the-us-for-the-development-of-farxiga